Dr Marina Garassino comments on the interim analysis of GALAXIES Lung-201 and the results from the randomized phase II RELATIVITY-104 study.

The interim analysis of GALAXIES Lung-201 was a phase II, randomized, open-label platform study of belrestotug plus dostarlimab in patients with previously untreated locally advanced or metastatic PD-L1 high (TPS ≥50%) non-small cell lung cancer.

Dr Garassino comments that in this interim analysis, belrestotug and dostarlimab demonstrat clinically meaningful anti-tumour activity at each dose and a manageable safety profile, supporting further evaluation in patients with previously untreated, unresectable LA/M PD-L1 high NSCLC.

The RELATIVITY-104 trial is a phase 2 study that investigates the combination of nivolumab, relatlimab (1:1), and chemotherapy as the initial treatment for stage IV or recurrent NSCLC.

In this study, the combination of nivolumab and relatlimab with platinum-doublet chemotherapy shows improved clinical benefits compared to nivolumab and platinum-doublet chemotherapy, especially in the PD-L1 ≥ 1% and NSQ pre-specified subgroups.